1 - 5 of 5

Suzanne P. MacFarland, MD

Suzanne P. MacFarland Headshot

Dr. MacFarland's research focuses on syndromes that predispose to cancer development in children and adolescents. She has initiated several individual and collaborative research projects, working in pediatric polyposis syndromes and Li-Fraumeni syndrome. She is uncovering novel genomic drivers of disease and identifying biomarkers of cancer onset and progression.


John M. Maris, MD

John M. Maris

Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.


Shannon L. Maude, MD, PhD

Shannon L. Maude

Dr. Maude focuses on novel therapies for high-risk and relapsed pediatric acute lymphoblastic leukemia (ALL). She aims to identify new pediatric ALL treatments that are more effective, less toxic, and exhibit fewer side effects than existing cancer therapies.


Yael P. Mossé, MD

Yael P. Mossé

Dr. Mossé's research goal is to improve cure rates for the childhood cancer neuroblastoma by discovering the genetic basis of the disease and translating rational therapeutic opportunities to the clinic. She studies the contribution of DNA sequence variations and activation mutations of anaplastic lymphoma kinase (ALK) genes on the development and progression of both inherited and acquired forms of neuroblastoma.


Sogol Mostoufi-Moab, MD, MSCE

Sogol Mostoufi-Moab Headshot

Dr. Mostoufi-Moab's clinical and research program is focused on endocrine late effects after childhood cancer therapy. She has unique dual training in pediatric endocrinology and oncology with a master's degree in clinical epidemiology. The goal of her research program is to pursue a mechanistic understanding of metabolic and endocrine disorders that occur due to cancer therapy.